Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
December 18, 2023 07:30 ET
|
POINT Biopharma
BEDFORD, Mass. and INDIANAPOLIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus) (NASDAQ: LNTH) and POINT Biopharma Global Inc. (POINT) (NASDAQ: PNT) today announced...
POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
November 13, 2023 07:30 ET
|
POINT Biopharma
INDIANAPOLIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands
September 18, 2023 08:00 ET
|
POINT Biopharma
INDIANAPOLIS and SCHLIEREN-ZURICH, Switzerland, Sept. 18, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery,...
Immuno-Oncology Clinical Trials Market Size & Share to Surpass $18.1 Billion by 2030 | Vantage Market Research
September 07, 2023 06:22 ET
|
Vantage Market Research
WASHINGTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- As per Vantage Market Research, the Global Immuno-Oncology Clinical Trials Market has been steadily growing over the years due to increasing incidence...
POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
August 14, 2023 07:30 ET
|
POINT Biopharma
Enrollment in PNT2002's SPLASH trial is complete and topline data is expected in the fourth quarter of 2023 Next-generation actinium-225 PSMA program PNT2001 phase 1 trial design released; first...
ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177
July 31, 2023 09:00 ET
|
POINT Biopharma
GARCHING / MUNICH, Germany and INDIANAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and POINT Biopharma Global Inc....
POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands
June 26, 2023 07:45 ET
|
POINT Biopharma
INDIANAPOLIS and SYDNEY, Australia, June 26, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and...
POINT Biopharma Expands Its Research with Next-Generation Isotopes, Publishing New Preclinical Data at SNMMI’s Annual Congress
June 26, 2023 07:30 ET
|
POINT Biopharma
Auger electron and beta emitting isotope terbium-161 was paired with POINT’s FAP-targeted PNT6555 ligand and showed robust anti-tumor efficacy, similar to actinium-225 and lutetium-177 labeled PNT6555...
POINT Biopharma Announces Appointment of Dr. Bridget Martell to its Board of Directors
June 12, 2023 08:00 ET
|
POINT Biopharma
INDIANAPOLIS, June 12, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
POINT Biopharma to Host Virtual Investor Day on Tuesday, June 20, 2023
June 07, 2023 07:00 ET
|
POINT Biopharma
Register online today at: https://hub.pointbiopharma.com/investor-day-june-2023 INDIANAPOLIS, June 07, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”),...